Sasanka M. Handunnetti

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S. Tam, Mary Ann Anderson, Christiane Pott et al. · New England Journal of Medicine · 2018 · 417 citations

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew et al. · Blood Advances · 2022 · 89 citations · Full text

Hematological Malignancy, Btk Leu528trp Mutation, Oncology +15

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti et al. · Blood · 2020 · 84 citations · Full text

Clonal hematopoiesis, myeloid disorders and <i>BAX</i>-mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler et al. · Blood · 2021 · 71 citations · Full text

Hematological Malignancy, Simultaneous Bcl2 Mutations, Oncology +14

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

Anthony R. Mato, Lindsey E. Roeker, John N. Allan et al. · American Journal of Hematology · 2018 · 70 citations · Full text